Survival Outcomes in Stage III to IV Melanoma Before and After the Immunotherapy Era: Persistent Racial and Socioeconomic Disparities
Although survival has improved in the immunotherapy era, inequities by age, race, sex, insurance, and treatment setting persist. Addressing barriers to timely diagnosis, specialized care, and immunotherapy access remains critical for achieving equitable outcomes in melanoma.
Authors
- Pranali Santhoshini Pachika (ORCID: https://orcid.org/0009-0004-5264-5860)
- Goetz Kloecker (ORCID: https://orcid.org/0000-0003-4726-3062)
- Shreyas Kalantri (ORCID: https://orcid.org/0000-0002-6871-024X)
- Tyler Jones
- Maiying Kong (ORCID: https://orcid.org/0000-0002-7313-9084)
- Jason Chesney (ORCID: https://orcid.org/0000-0003-0217-8278)
Institutions
- University of Louisville (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1200/op-25-00433
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05